GNOM stock forecast, quote, news & analysis

Key Takeaways

• GNOM is a passively managed exchange-traded fund (ETF) that tracks the Solactive Genomics Index, targeting companies advancing genomic science, gene editing, sequencing, and genetic medicine.
• The fund holds roughly 50 securities, concentrated in healthcare and biotechnology, with top positions including Moderna, Twist Bioscience, 10x Genomics, and Illumina.
• Over the trailing 30 days, GNOM has traded roughly flat to slightly lower, while the trailing three-month trend has been notably stronger.
• The portfolio carries a net expense ratio of 0.50% and approximately $102 million in assets under management (AUM).
• Principal themes are structural growth in genomics and precision medicine, offset by elevated volatility, unprofitable-biotech risk, and sensitivity to interest rates and risk sentiment.
• Investors can review additional analysis, including Price Targets and Forecast pages, for deeper insight into GNOM.
• Explore Trending AI Robots to discover automated trading strategies and market signals.

Global X Genomics & Biotechnology ETF (GNOM) Overview

The Global X Genomics & Biotechnology ETF seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index. The strategy invests in exchange-listed companies positioned to benefit from advances in genomic science and biotechnology, including gene editing, genomic sequencing, genetic medicine and therapy, computational genomics, and related applications.

GNOM is a non-diversified, passively managed index-tracking fund launched in April 2019. It holds approximately 50 securities with a heavy concentration in the healthcare sector, where biotechnology is the dominant industry. The top holdings include Moderna (MRNA), Twist Bioscience (TWST), 10x Genomics (TXG), Illumina (ILMN), and Guardant Health (GH), with additional weight in Natera (NTRA), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceutical (BMRN). The top 10 holdings typically account for a substantial share of net assets, and the portfolio is overwhelmingly weighted toward U.S.-listed companies. The net expense ratio is 0.50%.

Industry and Thematic Landscape

GNOM operates at the intersection of healthcare innovation and high-growth, high-volatility biotech. Structural drivers, including falling sequencing costs, the expansion of gene-editing platforms such as CRISPR-based therapies, and the growing adoption of liquid-biopsy diagnostics, continue to underpin long-term demand. At the same time, the segment is sensitive to broader risk appetite, because many constituents are early-stage companies with limited current earnings.

The macroeconomic backdrop matters disproportionately for this fund. Biotech valuations are highly sensitive to interest-rate expectations, since future cash flows are discounted more heavily when rates rise. Inflation and monetary policy, clinical-trial outcomes, regulatory decisions at agencies such as the U.S. Food and Drug Administration, and capital-market conditions for fundraising all influence the sector. Competition from larger pharmaceutical acquirers and the pace of mergers and acquisitions (M&A) also shape sentiment across the genomics complex.

Performance and Positioning Snapshot

Over the trailing 30 days, GNOM has been broadly range-bound, edging roughly 1% lower as choppy trading in October offset a late-September advance. This near-term consolidation followed a much stronger stretch: over the trailing three months, the fund advanced on the order of 23%, reflecting a mid-summer breakout that lifted the portfolio from the mid-$50s toward the high-$60s per share.

That quarterly move was consistent with a broad biotech re-rating driven by renewed investor interest in weight-loss and precision-medicine pipelines, improved funding conditions, and strength in several large holdings. Moderna, the fund's largest position, has been a standout contributor over the trailing year, while diagnostic and sequencing names such as Natera, Guardant Health, and 10x Genomics have also rallied. These gains have been accompanied by elevated realized volatility, consistent with GNOM's historically high annualized volatility, which has frequently exceeded 30%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility measures, AI-generated signals, market trends, price patterns, and customizable filters. The tool is designed to help users surface trending securities, breakout candidates, and emerging trading opportunities more efficiently than manual screening. For investors seeking to complement fundamental research with systematic, data-driven idea generation across sectors such as genomics and biotechnology, the AI Screener offers a practical way to monitor shifting market conditions and identify candidates worth further review.

2026 Outlook and Key Factors to Monitor

Several structural factors are likely to shape GNOM through 2026. Interest-rate policy and inflation expectations will remain central, given the portfolio's concentration in long-duration, often unprofitable biotech companies. A more accommodative monetary backdrop has historically been constructive for the sector, while persistent rate pressure tends to compress valuations.

Clinical and regulatory catalysts will also matter. Pipeline readouts across the fund's gene-editing, sequencing, and diagnostic holdings, along with FDA decisions, can produce outsized single-stock moves that ripple through the index. The earnings trajectory of major positions such as Moderna, Vertex, and Illumina warrants close attention, as does the pace of M&A and institutional capital flows into thematic healthcare strategies.

Finally, competition and product cycles in sequencing and diagnostics, the commercialization of genetic medicines, and reimbursement dynamics all represent both risks and opportunities. Investors should monitor these themes alongside the fund's elevated volatility and its concentration in a relatively small number of high-beta names.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations